← Leaderboards
Anne Frey Luetkemeyer
University Of California, San Francisco
$5,717,606
Attributed
$11,435,211
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,435,211 · 2
By mechanism
R01$11,435,211 · 2
Top collaborators
- Connie L Celum7 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Elizabeth Anne Bukusi$10,479,882
- Glenn-Milo Santos$8,436,377
- Haley Naik$887,490
- Michael Andrew Fischbach$20,742,968
- Adam Wayne Carrico$20,345,043
Others in their field
Other Emerging Leaders on “Sexually Transmitted Diseases”
- Kathleen Maletic Neuzil · Emory University$27,466,472
- Robert Wilson Frenck · Cincinnati Childrens Hosp Med Ctr$19,142,225
- Nadine Georges Rouphael · Emory University$10,262,035
- Angela Ramona Branche · University Of Rochester$10,119,005
- Gavin John Churchyard · Aurum Institute Npc$6,678,965
- Scot P Ouellette · University Of Nebraska Medical Center$6,167,697
Research focus
Sexually Transmitted DiseasesSan FranciscoIncidencePersonsPublic HealthSafetyGonorrheaHourEffectivenessParticipantPre-Exposure ProphylaxisProphylactic TreatmentAntibioticsEnrollmentAdherenceChlamydiaCitiesClinicBacteriaDoxycyclineMolecularMen Who Have Sex With MenEpidemicStaphylococcus Aureus
Grant awards (7)
The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratios$1,493,206
R01 · FY2025 · AI · contact PI
The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratios$1,628,180
R01 · FY2024 · AI · contact PI
Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men$1,412,385
R01 · FY2023 · AI · contact PI
Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men$2,586,659
R01 · FY2022 · AI · contact PI
Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men$1,431,796
R01 · FY2021 · AI · contact PI
Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men$1,464,310
R01 · FY2020 · AI · contact PI
Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men$1,418,675
R01 · FY2019 · AI · contact PI